Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

ALK +

ALK+ EGFR/HER2 Mutation, Untreated CNS Mets

KRAS+

Failed EGFR or ALK Inhibitor

Failed Platinum Chemo or EFG/ALK/R0S1 Inhibitor

Mets to Brain

LUN082 Phase II Anti- Tumor Activity of Oral EGFR/ HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)

PI: Wakelee

Xcovery

VAR0098 Phase I First-in-Human Dose-Escalation/ Safety/ Tolerability/ Pharmacokinetics of X-396 in Solid Tumors

PI: Wakelee

LUN0882 Phase II Oral Ceritinib Tx in ALK-Positive NSCLC Metastatic to the Brain and/or to Leptomeninges

PI: Neal Novartis

METS002 Phase II Oral Ceritinib Tx in ALK-Positive NSCLC Prior to Re-administration of Platinum Based Doublet Regimens

PI: Padda Stanford

TK1 1st/2nd Generation

LUN0083 Phase I/II AC010MA Previously Treated EGFRmut & Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)

PI: Wakelee

ACEA Bioscience

TK1 1st/3rd Generation

LUN0090 Phase I Afatinib&Necitumumab in EGFR Mutation+ NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance

PI: Padda

Pending

MAGE-A10

LUN0095 Phase I AZD9291 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI

PI: Padda

NCI

1st Priority

LUN0097 Phase II Regorafenib in Combo w/ Oral Methotrexate in KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)

PI: Neal

Ariad Pharmaceuticals

LUN0098 Phase I/II First-in-Human Dose-Escalation/ Safety/ Tolerability/ Pharmacokinetics of X-396 in Solid Tumors

PI: Wakelee

LUN0078 Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies

PI: Neal Adaptimmune Ltd

LUN0073 Phas IV Silver SNCIPC to Uncoated PleurX Pleural Catheter in Malignant Pleural Effusions

PI: Berry CareFusion 2200 Inc.

LUN0084 Phase II RRx-001 in Small, NSCLC Prior to Re-administration of Platinum Based Doublet Regimens

PI: Padda

EpicentRx, Inc

LUN0080 I/II MAGE-A10c796T in Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

PI: Neal

Adaptimmune Ltd

LUN0074 Pending

MAGE-A10

LUN0086 Phase I/II Afatinib&Necitumumab in EGFR Mutation+ NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance

PI: Padda

Pending

KEY

Pending

Open for Enrollment

Observational Study

Optinal Path

Immunotherapy

Enrollment on Hold

Extension Study

Link

Trial Posting